APA (7th ed.) Citation

M, S., S, J., V, V., R, S., SV, K., B, V., . . . R, R. (2026). Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: Phase 3 randomised clinical trial (PreVenTB trial). BMJ (Clinical research ed.), 393, e085716. https://doi.org/10.1136/bmj-2025-085716

Chicago Style (17th ed.) Citation

M, Singh, et al. "Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)." BMJ (Clinical Research Ed.) 393 (2026): e085716. https://doi.org/10.1136/bmj-2025-085716.

MLA (9th ed.) Citation

M, Singh, et al. "Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)." BMJ (Clinical Research Ed.), vol. 393, 2026, p. e085716, https://doi.org/10.1136/bmj-2025-085716.